HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Formula Industry Gets FTC's Antitrust Attention

Release Of Some Abbott EleCare, Kendmil Import From UK Get FDA OK

Executive Summary

Chairwoman Lina Khan was careful to note FTC isn’t investigating Abbott Nutrition’s manufacturing practices, its recall of products and shutdown of a plant and the supply shortage that followed.

You may also be interested in...



Urged By US FDA To Boost Infant Formula Supply, Additional Providers Still Must Wait For Approval

Patricia Hansen, CFSAN’s Office of Nutrition and Food Labeling deputy director and John Verbeten, deputy director for Import Operations Enforcement laid out the FDA's new enforcement guidance, and urged businesses with available formula to wait for approval before distributing formula in the US.

Biden Mandates Prioritizing Supplies For Infant Formula Production Over All Other Uses

Democrats and Republicans vote to approve $28m emergency finding for FDA formula programs proposed in bill introduced day earlier by Democrat leaders on Appropriations Committee. Biden deems Defense Production Act applicable to manufacturing formula products.

Merger Enforcement: FTC And Justice Department Casting Wide Net In Considering Changes

Agencies seek public comment on how they can modernize merger guidelines to enforce antitrust laws. List of questions, including what types of evidence show that a merger could reduce competition, indicate pharma and other mergers will face greater scrutiny.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

RS152554

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel